The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Apr. 24, 2007

Filed:

Oct. 16, 2002
Applicants:

Richard Martyn Angell, London, GB;

Nicola Mary Aston, Stevenage, GB;

Paul Bamborough, Stevenage, GB;

George Stuart Cockerill, London, GB;

Suzanne Joy Merrick, Stevenage, GB;

Kathryn Jane Smith, Stevenage, GB;

Ann Louise Walker, Stevenage, GB;

Inventors:

Richard Martyn Angell, London, GB;

Nicola Mary Aston, Stevenage, GB;

Paul Bamborough, Stevenage, GB;

George Stuart Cockerill, London, GB;

Suzanne Joy Merrick, Stevenage, GB;

Kathryn Jane Smith, Stevenage, GB;

Ann Louise Walker, Stevenage, GB;

Assignee:

Glaxo Group Limited, Greenford, Middlesex, GB;

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
C07C 233/65 (2006.01); A61K 31/165 (2006.01);
U.S. Cl.
CPC ...
Abstract

Compounds of formula (I): wherein when m is 0 to 4 R1 is selected from C1–6alkyl, C3–7cycloalkyl, C2–6alkenyl, —SO2NR4R5, —CONR4R5 and —COOR4; and when m is 2 to 4 R1 is additionally selected from C1–6alkoxy, hydroxy, NR4R5, —NR4SO2R5, —NR4SOR5, —NR4COR5, and —NR4CONR4R5; R2 is selected from hydrogen, C1–6alkyl and —(CH2)n-C3–7cycloalkyl; R3 is the group —CO—NH—(CH2)p-R6; U is selected from methyl and halogen; W is selected from methyl and chlorine; V and Y are each selected independently from hydrogen, methyl and halogen; m is selected from 0, 1, 2, 3 and 4 wherein each carbon atom of the resulting carbon chain may be optionally substituted with one or two groups selected independently from C1–6alkyl; n is selected from 0, 1, 2 and 3; p and r are independently selected from 0, 1 and 2; s is selected from 0, 1 and 2; or pharmaceutically acceptable salts or solvates thereof, and their use as pharmaceuticals, particularly as p38 kinase inhibitors


Find Patent Forward Citations

Loading…